[HTML][HTML] Evaluation of the early-phase [18F] AV45 PET as an optimal surrogate of [18F] FDG PET in ageing and Alzheimer's clinical syndrome
M Vanhoutte, B Landeau, S Sherif, V de la Sayette… - NeuroImage: Clinical, 2021 - Elsevier
Abstract Dual-phase [18 F] AV45 positron emission tomography (PET) is highly promising in
the assessment of neurodegenerative diseases, allowing to obtain information on both …
the assessment of neurodegenerative diseases, allowing to obtain information on both …
[18F]-D3FSP β-amyloid PET imaging in older adults and alzheimer's disease
Abstract Purpose [18F]-D3FSP is a new β-amyloid (Aβ) PET imaging tracer designed to
decrease nonspecific signals in the brain by reducing the formation of the N-demethylated …
decrease nonspecific signals in the brain by reducing the formation of the N-demethylated …
18F-APN-1607 Tau Positron Emission Tomography Imaging for Evaluating Disease Progression in Alzheimer's Disease
X Xu, W Ruan, F Liu, Y Gai, Q Liu, Y Su… - Frontiers in Aging …, 2022 - frontiersin.org
Purpose 18F-APN-1607 is a novel tau positron emission tomography (PET) tracer
characterized with high binding affinity for 3− and 4-repeat tau deposits. The aim was to …
characterized with high binding affinity for 3− and 4-repeat tau deposits. The aim was to …
Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid …
Importance Tau positron emission tomography (PET) tracers have proven useful for the
differential diagnosis of dementia, but their utility for predicting cognitive change is unclear …
differential diagnosis of dementia, but their utility for predicting cognitive change is unclear …
Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease
Purpose [18 F] FDG is a commonly used neuronal injury biomarker for early and differential
diagnosis of dementia. Typically, the blood supply to the brain is closely coupled to glucose …
diagnosis of dementia. Typically, the blood supply to the brain is closely coupled to glucose …
Correlation between brain 18F-AV45 and 18F-FDG PET distribution characteristics and cognitive function in patients with mild and moderate Alzheimer's disease
J Jing, F Zhang, L Zhao, J Xie, J Chen… - Journal of …, 2021 - content.iospress.com
Background: Florbetapir (AV45) and fluorodeoxyglucose (FDG) PET imaging are valuable
techniques to detect the amyloid-β (Aβ) load and brain glucose metabolism in patients with …
techniques to detect the amyloid-β (Aβ) load and brain glucose metabolism in patients with …
18F–FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage
Purpose We aimed to identify the cortical regions where hypometabolism can predict the
speed of conversion to dementia in mild cognitive impairment due to Alzheimer's disease …
speed of conversion to dementia in mild cognitive impairment due to Alzheimer's disease …
Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease
A Drzezga, D Altomare, C Festari, J Arbizu… - European journal of …, 2018 - Springer
Purpose To assess the clinical utility of 18F-Fluorodeoxyglucose positron emission
tomography (FDG-PET) for detection of early signs of neurodegeneration in conditions of …
tomography (FDG-PET) for detection of early signs of neurodegeneration in conditions of …
Tau positron emission tomographic imaging in aging and early A lzheimer disease
Objective Detection of focal brain tau deposition during life could greatly facilitate accurate
diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and …
diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and …
Dual time-point [18F] florbetaben PET delivers dual biomarker information in mild cognitive impairment and Alzheimer's disease
L Florek, S Tiepolt, ML Schroeter… - Journal of …, 2018 - content.iospress.com
Background: Current research diagnostic criteria for Alzheimer's disease (AD) and mild
cognitive impairment (MCI) due to AD include biomarkers to supplement clinical testing …
cognitive impairment (MCI) due to AD include biomarkers to supplement clinical testing …